Efficacy of SENS-111 in Patients Suffering From Acute Unilateral Vestibulopathy

Completed · Phase 2 · Has a placebo group

Conditions studied: Acute Unilateral Vestibulopathy (AUV)

In brief

A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 2 dose-regimens of orally administered SENS-111 (100mg and 200mg) given during 4 days in patients suffering from Acute Unilateral Vestibulopathy (AUV)

Key facts

Study ID
NCT03110458
Run by
Sensorion
People needed
107
Starts
2017-08-16
Expected to finish
2019-10-15
Last updated by the study team
2020-10-27

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.